|
Placebo group (n = 20)
|
Vitamin D group (n = 20)
|
Pa
|
---|
Baseline
|
End-of-trial
|
Change
|
Baseline
|
End-of-trial
|
Change
|
---|
Vitamin D (ng/mL)
|
11.0 ± 2.4
|
10.9 ± 2.1
|
-0.1 ± 0.6
|
10.5 ± 2.5
|
21.7 ± 5.9
|
11.2 ± 5.0
|
< 0.001
|
AMH (ng/mL)
|
8.7 ± 2.7
|
8.6 ± 2.5
|
-0.1 ± 0.5
|
7.7 ± 3.4
|
7.0 ± 3.1
|
−0.7 ± 1.2
|
0.02
|
FPG (mg/dL)
|
92.9 ± 5.5
|
93.5 ± 5.6
|
0.5 ± 3.0
|
90.3 ± 10.5
|
89.4 ± 10.6
|
−0.9 ± 7.4
|
0.42
|
Insulin (μIU/mL)
|
11.4 ± 1.9
|
11.1 ± 2.0
|
−0.3 ± 0.9
|
11.2 ± 2.2
|
9.8 ± 2.7
|
−1.4 ± 1.6
|
0.007
|
HOMA-IR
|
2.6 ± 0.5
|
2.5 ± 0.4
|
−0.1 ± 0.2
|
2.5 ± 0.7
|
2.2 ± 0.7
|
−0.3 ± 0.3
|
0.008
|
QUICKI
|
0.33 ± 0.008
|
0.33 ± 0.009
|
0.001 ± 0.004
|
0.33 ± 0.01
|
0.34 ± 0.02
|
0.009 ± 0.01
|
0.04
|
Triglycerides (mg/dL)
|
111.5 ± 35.5
|
117.4 ± 34.8
|
5.9 ± 13.2
|
105.3 ± 33.5
|
107.5 ± 38.1
|
2.1 ± 17.4
|
0.44
|
VLDL-cholesterol (mg/dL)
|
22.3 ± 7.1
|
23.5 ± 6.9
|
1.2 ± 2.6
|
21.1 ± 6.7
|
21.5 ± 7.6
|
0.4 ± 3.5
|
0.44
|
Total cholesterol (mg/dL)
|
197.1 ± 36.3
|
200.0 ± 36.5
|
2.9 ± 10.9
|
203.6 ± 26.6
|
198.5 ± 24.7
|
−5.1 ± 12.6
|
0.03
|
LDL-cholesterol (mg/dL)
|
124.9 ± 35.9
|
127.4 ± 35.3
|
2.5 ± 10.6
|
133.1 ± 21.1
|
128.7 ± 20.8
|
−4.5 ± 10.3
|
0.04
|
HDL-cholesterol (mg/dL)
|
49.9 ± 7.5
|
49.1 ± 8.2
|
−0.8 ± 3.9
|
49.4 ± 5.7
|
48.4 ± 5.4
|
−1.0 ± 2.8
|
0.81
|
- Data are means± SDs
- a Obtained from repeated measures ANOVA test
- AMH anti-Müllerian hormone, FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment-estimated insulin resistance, QUICKI quantitative insulin sensitivity check index